Additionally, it is known that resistances to platinum-based therapy correlate with high expression of ERCC1 [56] and can be reversed by blocking the interaction between ERCC1 and XPA, which is essential for NER, sensitizing cancer cells to NER substrates. This evidence concerns the gene XPA and cancer.